Jennison Associates LLC Dbv Technologies S.A. Transaction History

Jennison Associates LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 07, 2020	SELL	$6.75 - $11.15 $3.28 Million - $5.42 Million	-486,120 Closed	0 $0
Q3 2019 Nov 08, 2019	SELL	$8.57 - $10.72 $420,709 - $526,255	-49,091 Reduced 9.17%	486,120 $4.18 Million
Q2 2019 Aug 06, 2019	SELL	$7.58 - $10.0 $8,156 - $10,760	-1,076 Reduced 0.2%	535,211 $0
Q1 2019 May 10, 2019	BUY	$5.81 - $9.37 $3,369 - $5,434	580 Added 0.11%	536,287 $4.14 Million
Q4 2018 Feb 06, 2019	SELL	$5.75 - $21.85 $6.87 Million - $26.1 Million	-1,195,584 Reduced 69.06%	535,707 $3.44 Million
Q3 2018 Nov 08, 2018	BUY	$16.81 - $24.58 $396,026 - $579,080	23,559 Added 1.38%	1,731,291 $38.9 Million
Q2 2018 Aug 02, 2018	BUY	$18.6 - $24.94 $4.6 Million - $6.17 Million	247,523 Added 16.95%	1,707,732 $32.9 Million
Q1 2018 Apr 20, 2018	BUY	$20.86 - $26.6 $10.1 Million - $12.9 Million	486,295 Added 49.93%	1,460,209 $33.7 Million
Q4 2017 Jan 25, 2018	SELL	$20.9 - $49.36 $4.58 Million - $10.8 Million	-219,014 Reduced 18.36%	973,914 $24 Million
Q3 2017 Nov 03, 2017	BUY	$39.62 - $46.17 $47.3 Million - $55.1 Million	1,192,928	1,192,928 $50.6 Million

3.2K

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $824M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Jennison Associates LLC, based on Form 13F filings with the SEC.

Stay updated on Jennison Associates LLC with notifications on news.